Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Automatic Data Processing

Ecolab

Home Depot

Coca-Cola

UnitedHealth Group

Walmart

This article series provides a summary of upcoming ex-dividend dates. Relevant data and key statistics are provided in a summary table and include the next payout and pay date.

Upcoming Ex-Dividend Dates: March 9-22, 2021

Johnson & Johnson

iShares MSCI USA Momentum Factor ETF

SPDR Russell 1000 Momentum Focus ETF

Invesco DWA Momentum ETF

VictoryShares US Value Momentum ETF

Invesco S&P MidCap Momentum ETF

Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.

Momentum ETFs to Gain From the New Stimulus Optimism

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021

Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021

Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.

Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study

U.S. President Biden will meet with the chief executives of Johnson & Johnson and Merck & Co Inc at the White House on Wednesday after the companies recently announced a COVID-19 vaccine manufacturing deal, a White House official said on Monday.

Biden to meet on with CEOs of JNJ, Merck at White House on Wednesday: official

Merck stock popped Monday after its Ridgeback Biotherapeutics-partnered Covid-19 treatment showed promise in an interim analysis of a Phase 2 test. But Merck stock is still under pressure.

Merck Stock Pops After Covid Treatment Reduces Virus After 5 Days

Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics LP reported preliminary results from Phase 2a study evaluating molnupiravir, an experimental antiviral drug against COVID-19. The antiviral has shown positive effects with a significant reduction in the infectious virus in COVID-19 patients after five days of treatment.

Merck/Ridgeback Biotherapeutics' COVID-19 Antiviral Shows Promise

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Down 3.8% Since Last Earnings Report?

MIAMI & KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

MERCK Kommanditgesellschaft auf Aktien (MKGAF) Stefan Oschmann on Q4 2020 Results - Earnings Call Transcript

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Begins Tender Offer to Acquire Pandion Therapeutics

Merck Begins Tender Offer to Acquire Pandion Therapeutics

SAN JOSE, Calif., March 4, 2021 /PRNewswire/ -- Intermolecular, Inc. ("Intermolecular"), the trusted partner for materials innovation and a wholly-owned subsidiary of Merck KGaA, Darmstadt, Germany, today announced the relocation of the Silicon Valley Innovation Hub from Menlo Park to...

Merck KGaA, Darmstadt, Germany moves the Silicon Valley Innovation Hub to San Jose's Intermolecular site

Germany's Merck KGaA predicted further earnings gains in 2021 as an effort by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its supplies for biotech labs.

Germany's Merck KGaA predicts earnings gain in 2021

Merck & Co., Inc. (MRK) Presents at Cowen 41st Annual Health Care Conference (Transcript)

Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.

Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Barclays Global Healthcare Conference

Merck to Present at the Barclays Global Healthcare Conference

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021

Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021

Johnson & Johnson CEO Alex Gorsky discussed on Tuesday the company's unprecedented partnership with rival Merck to boost production of its Covid-19 vaccine.

Johnson & Johnson CEO on Merck vaccine partnership: 'Extraordinary times take extraordinary efforts'

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck with Funding to Expand Merck's Manufacturing Capacity

Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck's Manufacturing Capacity for COVID-19 Vaccines and Medicines

Merck will help rival drugmaker Johnson & Johnson produce its single-dose coronavirus vaccine, the White House said Tuesday. The two pharmaceutical giants have reached a “historic manufacturing partnership” to ramp up J&J's supply of its COVID-19 shot, which the feds cleared for emergency use on Saturday, White House Press Secretary Jen Psaki said.

Merck to help Johnson & Johnson produce COVID vaccine

Merck will reportedly step in to help Johnson & Johnson manufacture its coronavirus vaccine in a deal that binds two rival vaccine stocks. J&J is reportedly behind in production.

Merck, J&J Reportedly Forge Covid Vaccine Alliance — Here's What You Need To Know

The United States is using the Defense Production Act to equip drugmaker Merck & Co's plants to make Johnson & Johnson's just approved COVID-19 vaccine, White House press secretary Jen Psaki said on Tuesday.

White House using Defense Production Act to equip Merck plants for Johnson & Johnson vaccine

Two of the country's largest pharma companies will partner to speed up COVID-19 vaccine production. President Joe Biden will announce a partnership between Merck and Johnson & Johnson, senior administration officials told The Washington Post.

Merck will reportedly help produce Johnson & Johnson COVID-19 vaccine shots after failing to make its own (MRK, JNJ)

The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.

Coronavirus Update: U.S. COVID vaccine supply to be boosted by Merck helping make J&J vaccine

Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, a White House official said.

News for Merck Stock (MRK)